The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000565347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/04/2026
Date registered
Help: Date registered
4/05/2026
Date last updated
Help: Date last updated
4/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
BioSpine 2.0: A multimodal non-invasive neurorehabilitation program for people with chronic spinal cord injury
Scientific title
Effectiveness of a longitudinal, multimodal, non-invasive neurorehabilitation program delivered in repeated 6-month intervention blocks for people with chronic complete and incomplete spinal cord injury.
Additional trial identifiers [1] 316981 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records
ACTRN12622001272785 - extension.

This study differs from the previous one (ACTRN12622001272785) for use of transcutenous spinal cord stimulation, for different inclusion criteria now allowing people with incomplete spinal cord injury to participate, and for the delivery in 6-month blocks.

Health condition
Health condition(s) studied:
traumatic chronic spinal cord injury 341442 0
Condition category
Condition code
Neurological 337505 337505 0 0
Other neurological disorders
Physical Medicine / Rehabilitation 337754 337754 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Study Devices
The following non-invasive devices will be used as part of the intervention:

Wearable wireless EEG headset (custom-developed at Griffith University, with dry electrodes; or equivalent commercial device). This device non-invasively records low-voltage biosignals from the surface of the scalp using electrodes that are compatible with hair and optimised for comfort.

Functional electrical stimulation (FES) uses an electric current to externally stimulate muscles to facilitate movement. Surface electrodes consisting of adhesive hypoallergenic patches (Pals Platinum, Axelgaard Manufacturing Co Ltd, USA) are applied over the muscle groups of the lower limbs bilaterally (quadriceps, hamstrings, calves, and tibialis anterior). The electrodes do not cause damage to the skin or skin surface. FES is non-invasive and widely used in rehabilitation. The RehaStim 2 or P24 Science (Hasomed, Magdeburg, Germany) will be used for this intervention.

Transcutaneous spinal cord stimulation uses an electric current delivered via self-adhesive surface electrodes (ValuTrode, Axelgaard Manufacturing Co Ltd, USA) placed on the dorsal aspect of the back overlying the thoracic (T11–T12) and lumbar (L1–L2) vertebrae, with return electrodes placed bilaterally over the iliac crests. Stimulation frequency ranges from 5–40 Hz and amplitude from 20–130 mA, individually optimised for each participant. This device is non-invasive and does not cause damage to the skin or underlying tissues.

Arm and leg cycling ergometer is a stationary motorised bicycle providing pedal and handle assistance. The RT300 (Restorative Therapies, Baltimore, US), THERA-Trainer Tigo (THERA-Trainer, Hochdorf, Germany), or equivalent device will be used. The device is wheelchair compatible and enables participants to perform combined upper and lower limb cycling without requiring a transfer.

Virtual reality (VR) involves visual and auditory simulated content delivered via a head-mounted display (Meta Quest 2/3, Facebook Technologies, LLC, or equivalent). VR provides a first-person view of the participant's avatar immersed in a naturalistic environment, creating an engaging and immersive cycling experience during rehabilitation.

BioWrap® is a neoprene garment developed at Griffith University to facilitate rapid and reproducible placement of stimulation electrodes and sensors, improve comfort, and reduce session setup time.

Dosage
The study comprises four consecutive 6-month interventions, for a total study duration of up to 24 months. Participants may enrol at the beginning of any intervention and participate in consecutive or non-consecutive blocks of 6-month interventions, independently of whether they belong to the drug arm or the control arm of the intervention. Within each 6-month intervention, participants will perform at least 150 minutes per week of progressive neurorehabilitation, distributed over 2 to 3 sessions per week. Each session lasts between 60 and 75 minutes.

Participants enrolled in the drug arm of the study will be administered 7.5 mg of buspirone hydrochloride orally twice daily, commencing at least one week prior to the start of the intervention and continuing throughout. Medication adherence will be monitored at each in-person session by querying participants about tablet intake since the previous session, and by requesting the return of unused tablets at the end of each month. Participants in the non-pharmacological arm will receive the same device-based intervention without buspirone.

The allocation to the drug arm or control arm of the study is determined by participant's choice in consultation with their primary physician. Participants elected to participate in one arm of the study cannot enroll in a different arm of the study if re-enrolling in one of the subsequent 6-month intervention blocks, but can re-enroll in the same arm.

Intervention
At least two weeks prior to commencing each intervention, participants will undergo an individualised optimisation protocol for electrical stimulation parameters. During 1–2 weeks of visits (2–3 sessions per week, approximately 1 hour each), spinal transcutaneous stimulation will be delivered in supine and seated positions while surface electromyography records spinally evoked potentials from key lower limb muscles. Stimulation amplitude and frequency combinations will be systematically assessed to identify the optimal recruitment profile for each participant's sensorimotor pools below the level of injury. These personalised parameters will be used throughout the intervention and reassessed monthly.

Each rehabilitation session is conducted by an experienced exercise physiologist or physiotherapist. At the beginning of each session, the participant is instrumented with FES surface electrodes on the main muscles of the lower limbs bilaterally, and self-adhesive spinal stimulation electrodes on the thoracic and lumbar spine. Wireless EMG and motion capture sensors may also be placed on the lower limbs to assess performance. A BioWrap® garment is used to securely hold electrodes and sensors in place. The participant approaches the cycling ergometer in their wheelchair (provided if necessary) and is secured to the device. They are then donned with the EEG headset and VR headset. The session begins with a passive cycling warmup of at least 5 minutes to reduce spasticity, during which no electrical stimulation is applied and motorised assistance is set to its minimum. Cadence begins at 20 revolutions per minute and is progressively increased toward a target maximum of 50 revolutions per minute (or a lower individualised maximum). The warmup concludes once the minimum duration has elapsed, the target cadence is reached, and no spasms are detected for at least 1 minute.

A brain-computer interface (BCI) calibration procedure (varying in length between 1 and 25 minutes) is then performed within the session wherein a virtual avatar performing cycling or rest is displayed, and the participant is asked to imagine performing the visualised movement. Following calibration, the training phase commences: the participant imagines cycling, and this motor intent — as decoded by the BCI — triggers coordinated electrical stimulation of the lower limb muscles and the spinal cord, while the motorised ergometer simultaneously provides pedal and handle assistance. BCI calibration data may be automatically updated during the training phase. Ergometer torque is continuously monitored to detect spasms; upon detection, electrical stimulation and motorised assistance are gracefully shut down to prevent the application of force during a spastic event.

Parameters of Electrical Stimulation
FES electrodes are positioned bilaterally on the hamstrings, quadriceps, calves, and tibialis anterior. Stimulation frequency is set to 25 Hz, with amplitude individually identified by manual muscle palpation for twitch response and capped at 80 mA. The timing and amplitude of stimulation is automatically modulated throughout the pedalling cycle to activate each muscle of the right amount to achieve the target cycling cadence only when muscles are in their mechanically advantageous phase.

For transcutaneous spinal cord stimulation, cathodal electrodes are placed over T11–L2 vertebrae and anodal return electrodes over both iliac crests. Stimulation frequency ranges from 5–40 Hz and amplitude from 20–130 mA, based on individually optimised parameters. Spinal stimulation is delivered synchronously with BCI-decoded motor intent and thereby delivered only when the participant is imagining to cycle..

Intervention code [1] 333727 0
Treatment: Devices
Intervention code [2] 333728 0
Treatment: Drugs
Description of the comparator or control
This is a non-randomised two-arm study. Both arms receive the same device-based intervention. The two arms differ only in the co-administration of a study drug.

The control arm receives the BioSpine 2.0 device-based intervention without pharmacological augmentation. Participants in this arm undergo the same session protocol, dosage (at least 150 minutes per week over 2–3 sessions per week), and outcome assessments as participants in the drug arm.

The pharmacological arm receives the same device-based intervention with the addition of buspirone hydrochloride (7.5 mg orally, twice daily), commencing at least one week prior to the start of each 6-month intervention and continuing throughout. Group comparisons between the two arms will be used to evaluate the effect of buspirone hydrochloride on neural recovery outcomes.

Within-subject comparisons across the four consecutive 6-month interventions will additionally be used to evaluate the effect of progressive modifications to the device parameters, including spinal stimulation electrode configuration and cycling modality.
Control group
Active

Outcomes
Primary outcome [1] 345017 0
Change of voluntary motor function .
Timepoint [1] 345017 0
Baseline and 6 months from the start of each intervention
Primary outcome [2] 345018 0
Change of somatosensory function
Timepoint [2] 345018 0
Baseline and 6 months from the start of each intervention
Secondary outcome [1] 460287 0
Isometric muscle strength of upper limb muscle groups
Timepoint [1] 460287 0
Baseline, 3 months, and 6 months from the start of each intervention
Secondary outcome [2] 460288 0
Exercise capacity
Timepoint [2] 460288 0
Baseline, 3 months, and 6 months from the start of each intervention
Secondary outcome [3] 460289 0
Upper limbs spasticity
Timepoint [3] 460289 0
Baseline, 3 months, and 6 months from the start of each intervention
Secondary outcome [4] 460290 0
Health-related quality of life
Timepoint [4] 460290 0
Baseline, 3 months, and 6 months from the start of each intervention
Secondary outcome [5] 460966 0
Isometric muscle strength of lower limb muscle groups
Timepoint [5] 460966 0
Baseline, 3 months, and 6 months from the start of each intervention
Secondary outcome [6] 460967 0
Lower limbs spasticity
Timepoint [6] 460967 0
Baseline, 3 months, and 6 months from the start of each intervention

Eligibility
Key inclusion criteria
Traumatic spinal cord injury classified as motor and sensory complete or incomplete (ASIA Impairment Scale A, B, or C)
Chronic injury, defined as more than 18 months post-injury
Age 18 years or older
Ability to participate in regular physical activity
Ability to understand training instructions and provide adequate feedback
Provision of written informed consent prior to any study procedures
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Osteoporosis with a T-score below -4.0 at the femoral neck
Fractures in the last 18 months
History of stem cell therapy in the last 5 years
Current use of baclofen or other antispasmodic medication
Existing renal or hepatic impairment
Orthopaedic conditions including joint instability
Epilepsy
Cardiac pacemaker or implanted defibrillator
Cognitive impairment that limits capacity to consent to or engage in the intervention
Concurrent significant head injury resulting in psychomotor deficit
Pregnancy
Skin breakdown that would limit ability to sit for 60 minutes
Any other complication that would prevent safe participation, as determined by the participant's primary physician

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 321579 0
Government body
Name [1] 321579 0
Motor Accident Insurance Commission
Country [1] 321579 0
Australia
Primary sponsor type
University
Name
Griffith University
Address
Country
Australia
Secondary sponsor category [1] 324378 0
None
Name [1] 324378 0
Address [1] 324378 0
Country [1] 324378 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320108 0
Griffith University Human Research Ethics Committee
Ethics committee address [1] 320108 0
Ethics committee country [1] 320108 0
Australia
Date submitted for ethics approval [1] 320108 0
25/01/2024
Approval date [1] 320108 0
03/04/2024
Ethics approval number [1] 320108 0
GU Ref No: 2024/152

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149458 0
A/Prof Claudio Pizzolato
Address 149458 0
G02 1.16 Griffith University Gold Coast Campus, 58 Parklands Dr, Southport, QLD 4215
Country 149458 0
Australia
Phone 149458 0
+61 7 5552 7066
Fax 149458 0
Email 149458 0
Contact person for public queries
Name 149459 0
Kyle Mulholland
Address 149459 0
G02 1.10 Griffith University Gold Coast Campus, 58 Parklands Dr, Southport, QLD 4215
Country 149459 0
Australia
Phone 149459 0
+61 412366028
Fax 149459 0
Email 149459 0
Contact person for scientific queries
Name 149460 0
Claudio Pizzolato
Address 149460 0
G02 1.16 Griffith University Gold Coast Campus, 58 Parklands Dr, Southport, QLD 4215
Country 149460 0
Australia
Phone 149460 0
+61 7 5552 7066
Fax 149460 0
Email 149460 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Data can be obtained upon email request to the principal investigator. Please contact Dr Claudio Pizzolato by emailing [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.